India's largest eye care chain, offering surgeries, consultations, opticals and eye-care pharma products.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 7 | 7 | 7 | 8 | 9 | 32 | 32 | 32 |
| Reserves | 242 | 177 | 206 | 622 | 1.3k | 1.8k | 1.9k | 2.0k |
| Borrowings | 162 | 185 | 633 | 857 | 966 | 961 | 983 | 1.1k |
| Other Liabilities | 339 | 417 | 179 | 336 | 445 | 837 | 873 | 850 |
| Total Liabilities | 751 | 787 | 1.0k | 1.8k | 2.8k | 3.7k | 3.8k | 3.9k |
| AssetsFixed Assets | 551 | 575 | 701 | 1.3k | 1.7k | 2.5k | 2.7k | 2.9k |
| CWIP | 8 | 11 | 28 | 99 | 118 | 153 | 163 | 234 |
| Investments | 1 | 0 | 0 | 34 | 471 | 264 | 208 | 152 |
| Other Assets | 192 | 201 | 295 | 397 | 416 | 724 | 693 | 676 |
| Total Assets | 751 | 787 | 1.0k | 1.8k | 2.8k | 3.7k | 3.8k | 3.9k |
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 103 | 99 | 164 | 233 | 346 | 360 | 519 |
| Cash from Investing | -85 | -46 | -155 | -509 | -914 | -750 | -308 |
| Cash from Financing | -73 | -37 | 35 | 303 | 553 | 382 | -220 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — |
| Free Cash Flow | -98 | 66 | 95 | 76 | 118 | 40 | 59 |
| FCF Margin | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (127.4×) and current (110.8×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 52.7% growth and a 111× exit, ₹467 only delivers your return if you pay ₹2,000. The price is currently baking in 18% growth.
EPS grows 52.7%/yr for 5 years, then fades to 6% over 2, exits at 111×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 52.7% | 6.43 |
| FY28 | 52.7% | 9.82 |
| FY29 | 52.7% | 14.99 |
| FY30 | 52.7% | 22.89 |
| FY31 | 52.7% | 34.95 |
| FY32 | 29.3% ·fade | 45.21 |
| FY33 | 6.0% ·fade | 47.92 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.